Sandoz Vietnam marks one year of independence with strong progress on patient access, partnerships and AMR awareness
Xem Tiếng Việt 
Sandoz, the global leader in generic and biosimilar medicines today announced that it reached over six million patients in Vietnam in the past year since its spin-off from Novartis in 2024. Through 14 key products, Sandoz Vietnam has delivered US$56 million in social savings, achieving an index of 2.9 (meaning for every 1 USD spent on Sandoz medicines, the healthcare system saves 2.9 USD).
“Our first year as Sandoz Vietnam has been one of purposeful growth. While staying true to our global mission, we’ve focused on understanding and addressing Vietnam’s evolving healthcare needs,” said Mr. Charaf Eddine Kadri, General Director of Sandoz Vietnam. “From expanding patient access to strengthening partnerships and supporting national health priorities, we’ve laid important groundwork for the future. We’re proud of the progress made and remain committed to doing more, together with our partners.”
In 2024, Sandoz signed MOUs with leading hospitals, including Ho Chi Minh City Oncology Hospital (March) and National Cancer Hospital (June). As part of the National Cancer Hospital collaboration, a hands-on nurse training workshop engaged nearly 250 healthcare professionals (HCPs). Building on positive feedback, a follow-up session at Cho Ray Hospital in August drew close to 150 HCPs.
These initiatives, among others, led to expanded use of Rituximab, Sandoz’s biosimilar for non-Hodgkin’s lymphoma. In 2024, over 2,000 patients accessed our product, marking a 48% increase over the previous year.
In December 2024, Sandoz launched a Pharmacoeconomics Advisory Board to for hospitals to share how they apply health economic principles to daily activities like medicine access and budgeting with the aim of helping hospitals reach more patients with more affordable options of the same high quality. The inaugural board brought together 15 experts from 15 major hospitals, followed by a local-level event attended by 50 participants.
The initiative expanded in Q1 2025 with engagement activities across 15 hospitals, involving over 600 interactions with key stakeholders. Throughout 2025, Sandoz plans to conduct 180 educational events and two national symposia, aiming to embed pharmacoeconomics as a strategic tool to improve access and resource use in hospitals.
To help tackle one of the world’s most urgent public health threats, Sandoz Vietnam ran a nationwide AMR awareness campaign in November 2024. TVC billboards were displayed across key cities for 30 days, reaching an estimated 500,000 people daily. On-ground activations in Ho Chi Minh City and Hanoi drew strong public interest, with nearly 1,200 people engaged in HCMC alone.
“AMR is one of the most urgent healthcare threats of our time,” added Kadri. “This campaign was our call to action for patients, caregivers, and communities to use antibiotics responsibly and safeguard the future of healthcare.”
In 2024, Sandoz also facilitated peer-to-peer exchange among top oncology centres. Over 300 hematology-oncology experts and specialists from the north and south joined three regional sessions held between April and August, fostering clinical knowledge-sharing across institutions.
As it enters its second year, Sandoz Vietnam remains focused on delivering high-quality, affordable medicines while scaling collaborations that enhance access and drive health outcomes. With continued investment in partnerships, education and policy engagement, the company is well-positioned to help shape a more sustainable and equitable healthcare landscape for Vietnam.
